Search Results

How Maryland's Prescription Drug Affordability Board affects patient access: statute, board actions, Maryland PDAB Back to PDAB Policy Center Information, updates, and engagement opportunities related to View PDF CANN Public Comment: Maryland PDAB Data Contracting Publication date: 6/18/25 Comment on Maryland View PDF CANN Public Comment: Maryland PDAB Meeting Materials Publication date: 3/19/25 Comment on Maryland View PDF CANN Comment: Maryland PDAB Cost Review Study Publication date: 5/10/24 Comment opposing Maryland's

Patient-centered tracking of 340B policy in Maryland: active bills, committee assignments, fact sheets Maryland 340B Watch Stay informed on state-level actions, proposed legislation, and advocacy efforts and press releases submitted regarding state 340B activity Current Legislative Session Activity in Maryland

a proven "Gold Standard" and pushing back on DSH-system concerns. 06/09/2026 CANN Written Comment: Maryland PDAB Cost Review Study Process Revisions (June 2026) Comment to the Maryland PDAB on proposed amendments PDAB Ongoing Board Developments (May 2026) Written comment to the Maryland PDAB on patient outreach PDAB March 2026 Written comment addressing Maryland PDAB's March 2026 meeting on implementation concerns PDAB Ongoing Board Developments (May 2026) Written comment to the Maryland PDAB on patient outreach

Colorado Maryland New Jersey Connecticut Massachusetts Ohio Illinois Michigan Oregon Iowa Minnesota Vermont 2024 The source spreadsheet behind CANN's ADA analysis — every PDAB-eligible drug across Colorado, Maryland Conditions Published: July 23, 2024 Original data analysis of every PDAB-eligible drug in Colorado, Maryland

Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland